Boceprevir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, PharmD

INDICATIONS

FDA

  • Boceprevir is indicated for the treatment of HCV (genotype1, used in combination with peg-INF + ribavirin) in adult patients with compensated liver disease, including cirrhosis.
    • Boceprevir may be used in either treatment-naïve patients or those who have failed previously interferon/ribavirin therapy.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: March 4, 2018